Robert T. Rhoad, Partner Washington, D.C.
rrhoad@crowell.com
Phone: +1 202.624.2545
1001 Pennsylvania Avenue NW
Washington, D.C. 20004-2595

Robert "Bob" Rhoad is a partner in the Washington, D.C. office of Crowell & Moring and is active in the firm's Health Care, Government Contracts, White Collar & Regulatory Enforcement, and Antitrust groups. He is co-leader of both the firm's Government Procurement Fraud/False Claims Act and Health Care Litigation Teams. Bob is a trial lawyer with over 20 years of experience and his primary area of focus is complex litigation involving the federal False Claims Act, state false claims laws, fraud and abuse matters, and criminal and civil government enforcement actions initiated by qui tam relators (whistleblowers) and/or brought by federal and state governmental authorities. In recognition of his success, among other accolades, Bob has been listed as a Washington, D.C. "Super Lawyer" by Super Lawyers® in the Civil Litigation category and as a "Top Lawyer" by Washingtonian magazine in the Whistleblower Defense category – one of only six attorneys so designated.

In addition to representing government contractors and health care entities as defendants in national litigation, Bob has significant experience in the successful representation of health care industry clients as plaintiffs in affirmative litigation to recover damages suffered due to anticompetitive conduct, as well as the fraudulent marketing and sales of defective pharmaceuticals and medical devices by manufacturers. His recoveries for clients in such cases to date range in the hundreds of millions of dollars.

Since 2002, he has taught litigation and trial courses as an adjunct professor at The George Washington University Law School. He has also presented at numerous national conferences and has published scores of articles over the years. In 2015, he was the recipient of the prestigious Burton Award for Distinguished Legal Writing. Bob also currently serves as the co-chair of the American Bar Association Health Law Section's Ethics and Professionalism Committee and is vice chair of its Health e-Source Editorial Board. 

Prior to entering private practice in 1999, Bob served for nearly six years as an attorney/officer in Navy Judge Advocate General's (JAG) Corps in successive assignments as prosecutor, defense counsel, and civil litigation attorney. As both a prosecutor and defense counsel, Bob gained significant trial experience as lead counsel in numerous felony cases involving complex fraud issues. As a civil litigation attorney, he served as lead agency counsel for the Department of the Navy working with U.S. Attorney Offices throughout the country in the litigation and trial of cases on behalf of the Department of the Navy. He attained the rank of lieutenant commander and received numerous awards and commendations for his service as a Navy judge advocate and with the federal government.

False Claims Act / Qui Tam Matters

  • United States ex rel. _____ v. _____ (under seal) (E.D. Va.). Lead Defense Counsel for national government I.T. contractor in connection with a False Claims Act/qui tam investigation regarding alleged fraud by subcontractor related to contract with federal agency.  Case remains pending.
  • United States ex rel. Lori Morsell v. Symantec Corporation, Case No. 1:12-0800-RC (D.D.C.). Lead Defense Counsel for multiple former Symantec Corporation employees in connection with a False Claims Act/qui tam action alleging fraud related to the sale of products and services under GSA schedule. The Government intervened and Symantec’s motion to dismiss is pending. See United States ex rel. Lori Morsell v. Symantec Corporation, Case No. 1:12-0800-RC (D.D.C.).
  • _____ v. _____ (D.D.C.). Lead Defense Counsel for publicly chartered private corporation in connection with a False Claims Act retaliation action alleging fraud. The case was settled for nominal amount and dismissed following our filing of a motion to dismiss.
  • United States ex rel. Prescott Lovern v. The Prudential Insur. Co. Of America, et al., Case No. 1:12-cv-00704 (D.D.C.). Lead Defense Counsel for Zurich American Insur. Co. in connection with a False Claims Act/qui tam action alleging fraud related to grant funding for a renewable energy project under the American Recovery and Reinvestment Act of 2009. The Government did not intervene. All claims were dismissed with prejudice and relator’s appeal to the D.C. Circuit was also dismissed. See United States ex rel. Prescott Lovern v. The Prudential Insur. Co. Of America, et al., Case No. 1:12-cv-00704 (D.D.C.) (Minute Order, January 22, 2014); United States ex rel. Prescott Lovern v. Deutsche Bank Trust Co. Americas, et al., No. 14-7186 (D.C. Cir.) (Per Curiam opinion, May 6, 2015).
  • United States ex rel. Joseph Morgan v. ManTech International Corporation, et al., Case No. 1:13-cv-01289-TSC (D.D.C.). Lead Defense Counsel for ManTech International Corporation in connection with a False Claims Act/qui tam action alleging fraud related to maintenance of armored vehicles in Afghanistan.  The Government did not intervene and the case was dismissed. See United States ex rel. Joseph Morgan v. ManTech International Corporation, et al., Case No. 1:13-cv-01289-TSC (D.D.C.) (Order, September 4, 2014).
  • United States ex rel. Robert R. Purcell v. MWI Corp., et al., Case No. 1:98-CV-02088 (D.D.C.). Lead Defense/Trial/Appellate Counsel for Moving Water Industries, Inc. (MWI) in connection with a False Claims Act/qui tam action alleging fraud related to submissions to the Export-Import Bank of the United States, which financed loans issued to several Nigerian states for their purchase of pumping/irrigation equipment from MWI in the early 1990s. The Government intervened and claimed trebled damages in excess of $222 million. During the month-long jury trial in federal court in 2013, the Government's common law claims were dismissed with prejudice and the trial resulted in a judgment of $0 damages on the Government's False Claims Act claims.  The case is currently on appeal.  See United States ex rel. Robert Purcell v. Moving Water Industries, Inc., et al., --- F.Supp.2d----, 2014 WL 521524 (D.D.C.) (February 10, 2014); United States ex rel. Robert Purcell v. Moving Water Industries, Inc., No. 14-5210 (D.C. Cir.).
  • United States ex rel. _____ v. _____ (under seal) (C.D. Cal.).  Lead Defense Counsel for national telecommunications firm in a False Claims Act/qui tam retaliation case involving allegations of false claims in connection with the provision of voice-mail services for several government agencies. The Government did not intervene. Retaliation claims settled for nuisance value and dismissed with prejudice.
  • United States et al. ex rel Patricia Critz v. ProStrakan, Inc., Case No. 2:12-cv-02425 (W.D. Tenn.). Lead Defense Counsel for brand name pharmaceutical company, ProStrakan, Inc., in a False Claims Act/qui tam retaliation case involving allegations of off-label promotion. The Government did not intervene. Retaliation claims settled for nuisance value and case was dismissed with prejudice. See United States et al. ex rel Patricia Critz v. ProStrakan, Inc., Case No. 2:12-cv-02425 (W.D. Tenn.) (Judgment, December 20, 2013). 
  • United States ex rel. Michael Lindley v. The Gallup Organization, (D.D.C.). Lead Defense Counsel for The Gallup Organization in a False Claims Act/qui tam action involving parallel criminal and civil proceedings involving allegations of violations of 18 U.S.C. § 207 (conflicts of interest), 18 U.S.C. § 287 (criminal False Claims Act), 41 U.S.C. § 423 (Procurement Integrity Act) and the civil False Claims Act. The False Claims Act claims alleged improper bid pricing in connection with nearly 30 different contracts with eight separate federal agencies. Government intervened only as to claims related to three contracts with two federal agencies. Criminal allegations resolved through non-prosecution agreement and civil False Claims Act allegations resolved just prior to filing of motions to dismiss for small fraction of alleged single damages and previously imposed suspension was lifted.
  • United States ex rel _____ v. _____ (under seal) (E.D. Va.). Lead Defense Counsel for physician in a False Claims Act/qui tam action involving allegation of "upcoding" and billing for services not rendered for palliative/hospice care. Allegations involving physician client resolved with no criminal or civil liability.
  • United States ex rel. _____ v. _____, (under seal) (C.D. Cal.). Lead Defense Counsel for national telecommunications firm in a False Claims Act/qui tam action alleging retaliation related to alleged False Claims Act violations related to provision of telecommunication services to government agencies. Case successfully resolved for nuisance value through mediation and dismissed with prejudice.
  • United States ex rel. Ven-A-Care of the Florida Keys v. Actavis Mid Atlantic LLC, et al., Case No. 08-cv-10852 (D. Mass.). Lead Defense Counsel for Actavis Mid Atlantic LLC in False Claims Act/qui tam action alleging pharmaceutical price reporting fraud in violation of the False Claims Act in connection with In re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, Case No. 01-CV-12257 (D. Mass.). The Government did not intervene.  Case successfully resolved through settlement following protracted litigation and dismissed with prejudice.
  • Commonwealth of Kentucky, ex rel. Jack Conway, Attorney General v. Alpharma USPD, Inc., et al., Case No. 04-CI-1487, Commonwealth of Kentucky, Franklin Circuit Court, Div. I. Lead Defense Counsel for Actavis Mid Atlantic LLC and its affiliated companies in case alleging violations of the Kentucky Consumer Protection Act, Medicaid Fraud Statute, False Advertising Statute, and General Recovery Statute. Case successfully resolved through settlement following summary judgment motion hearing and on eve of trial for fraction of claimed single damages and dismissed with prejudice.
  • United States v. John B. Torkelsen, et al., Case No.2:06-CV-05674 (E.D. Pa.). Lead Defense Counsel for individual defendants in a False Claim Act case alleging fraud under the U.S. Small Business Administration's Small Business Investment Company (SBIC) Program. The False Claims Act action was brought in conjunction with separate receivorship and tort actions against these and other defendants. Following litigation, the False Claims Act claims were resolved successfully as part of a global resolution of all pending actions, including the receivership action for which judgment had previously been entered and for less than the judgment previously imposed.
  • United States ex rel. Patricia Howard v. USA Environmental, Inc., Case No. 8:06-CV-00027 (M.D. Fla.); Patricia Howard v. USA Environmental, Inc., Case No. 09-11866 (11th Cir.). Lead Defense/Appellate Counsel for USA Environmental, Inc. (USAE) in qui tam action under the False Claims Act alleging fraud by USAE in conjunction with contract with the U.S. Army to dispose of unexploded ordinance in Iraq and retaliation. The Government did not intervene. All fraud claims were dismissed with prejudice upon USAE's motion to dismiss. Amended complaint was then filed on retaliation claim and it was dismissed with prejudice upon USAE's renewed motion to dismiss. Judgment entered in favor of USAE and against the Relator on all claims alleged. Affirmed by 11th Circuit on appeal. See U.S. ex rel. Patricia Howard v. USA Environmental, Inc., 2009 WL 113444 (M.D. Fla.) (dismissing FCA fraud claims with prejudice and FCA retaliation claim without prejudice); United States ex rel. Patricia Howard v. USA Environmental, Inc., 2009 WL 652433 (M.D. Fla.) (dismissing FCA retaliation claim and entire case with prejudice); United States ex rel. Patricia Howard v. USA Environmental, Inc., No. 09-11866 (11th Cir. 2010) (Per Curiam decision affirming dismissal with prejudice) (March 5, 2010).
  • United States ex rel. DRC, Inc. et al. v. Custer Battles, LLC, et al. , Case No. 1:04-CV-00199 (E.D. Va.); U.S. ex rel. DRC, Inc. et al. v. Custer Battles, LLC, et al., Case No. 07-1220 (4th Cir.). Lead Defense/Trial/Appellate Counsel for Custer Battles Defendants (i.e., Custer Battles LLC and its affiliated companies and principles) in qui tam action under the False Claims Act alleging fraud in conjunction with two contracts Custer Battles, LLC had with the Coalition Provisional Authority (CPA) in Iraq to provide security support services for the Baghdad International Airport (BIAP Contract) and support services for the Iraqi Currency Exchange Program (ICE Contract). Summary judgment granted in favor of the Custer Battles Defendants on all of the False Claims Act fraud claims regarding the BIAP Contract. Judgment as a matter of law was granted in favor of Custer Battles Defendants on all of the False Claims Act fraud claims regarding the ICE Contract following a month-long trial. The Government did not intervene in the District Court proceedings, but did file a brief and present argument as amicus curiae on appeal to the 4th Circuit. On appeal, the judgment on the BIAP Contract claims was affirmed and the judgment on the ICE Contract claims was reversed and remanded for further proceedings. See U.S. ex rel. DRC, Inc., et al. v. Custer Battles, LLC, et al., 376 F.Supp.2d 617 (E.D. Va. 2005) (granting in part and denying in part summary judgment); U.S. ex rel. DRC, Inc., et al. v. Custer Battles, LLC, et al., 444 F.Supp.2d 678 (E.D. Va. 2006) (judgment as a matter of law and dismissal of ICE Contract claims); U.S. ex rel. DRC, Inc., et al. v. Custer Battles, LLC, et al., 472 F.Supp.2d 787 (E.D. Va. 2007) (summary judgment on and dismissal of BIAP Contract claims); U.S. ex rel. DRC, Inc., et al. v. Custer Battles, LLC, et al., 562 F.3d 295 (4th Cir. 2009).
  • U.S. ex rel. Rory Mayberry, et al. v. Custer Battles, LLC, et al., Case No. (E.D. Va.). Consulting Counsel for Custer Battles, LLC (and its affiliated companies and principles) in qui tam action under the False Claims Act alleging fraud and improper transfer by Custer Battles, LLC of its contracts with the Coalitional Provisional Authority (CPA) in Iraq and Iraq assets to an alleged "sham" successor entity to evade the effect of a Government suspension order. The Government did not intervene in the case. While summary judgment motions were pending, the case was dismissed and Relator Mayberry and his counsel were admonished and sanctioned for egregious discovery violations.
  • United States ex rel. Bradford Hunt, et al. v. Merck-Medco Managed Care, LLC, et al., Case No. 00-cv-737 (E.D. Pa.). Plaintiffs'/Relators' Counsel in qui tam action under the False Claims Act alleging fraud by a national pharmacy benefit management company (PBM) related to services performed for federal health plans. The Government intervened in the case, which was litigated aggressively for several years, and which was settled for approximately $185 million just prior to summary judgment/trial. It was one of the largest False Claims Act settlements at the time and was the largest civil settlement in Pennsylvania in 2006-2007. See U.S. ex rel. Hunt, et al. v. Merck- Medco Managed Care, LLC, et al. , 336 F. Supp. 2d 430 (E.D. Pa., 2004); U.S. ex rel. Hunt, et al. v. Merck- Medco Managed Care, LLC, et al., 340 F. Supp. 2d 554 (E.D. Pa. 2004); U.S. ex rel. Hunt, et al. v. Merck- Medco Managed Care, LLC, et al., 223 F.R.D. 330 (E.D. Pa. 2004).
  • U.S. ex rel. _____ v. _____, (under seal) (D. Mass.). Defense Counsel for a large, national health managed care organization in (criminal and civil) False Claims Act case involving allegations of fraud and conspiracy related to agreements with several pharmaceutical manufacturers to purportedly circumvent provisions under the Medicaid "Best Price" statute. Initially, the Government considered our client as the "hub" of the alleged conspiracy. Although several other subjects of the Government's investigation (pharmaceutical manufacturers) eventually entered criminal pleas and/or reached multi-million dollar civil settlements with the Government (involving Corporate Integrity Agreements), we successfully convinced the Government to decline further prosecution and to abandon civil enforcement against our client, relieving it of any further criminal or civil exposure and avoiding the imposition of a Corporate Integrity Agreement.
  • U.S. ex rel. _____ v. _____, (under seal) (S.D. Ohio). Lead Defense Counsel for national durable medical equipment (DME) manufacturer/supplier in qui tam action brought under the False Claims Act alleging fraud related to certifications made in conjunction with sales of medical equipment through federal programs. The Government did not intervene and the case was dismissed.
  • U.S. ex rel. _____ v. _____, (under seal) (S.D. Ohio). Lead Defense Counsel for national manufacturer of armored vehicles/Defense contractor in qui tam action brought under the False Claims Act alleging fraud related to certifications made in conjunction with armored vehicles manufactured under contract with the Army. The Government did not intervene and the case was dismissed.
  • U.S. v. Valenzuela Engineering, Inc., (E.D. Cal.). Defense Counsel for national engineering and construction firm in (criminal and civil) False Claims Act case alleging various acts of fraud related to contracts with the Air Force and U.S. Army Corps of Engineers. Our client, which was originally central to the Government's investigation, was completely vindicated and was neither indicted nor entered into a civil settlement with the Government.
  • U.S. ex rel: _____ v. _____, (under seal) (D.D.C.). Defense Counsel for large, non-profit humanitarian relief organization/NGO in qui tam action brought under the False Claims Act alleging fraud in conjunction with contracts/grants with the U.S. Agency for International Development to support various agri-business programs in eastern Europe. The Government did not intervene and the case was dismissed.
  • U.S. v. Powell, et al., Case No. 00cr0054-02 (D.D.C.). Defense Counsel for alleged co-conspirator in criminal case involving various fraud allegations related to contracting activities in conjunction with the sale of computer equipment to the Government through contracts with the National Aeronautics and Space Administration (NASA). As a result of our efforts, our client was not indicted and the Government declined to pursue criminal prosecution or civil settlement.

Health Care/Antitrust & Other Affirmative Recovery Matters

  • In re Flonase Antitrust Litig., Case No. 12-cv-4212 (E.D. Penn.).  Lead Counsel for group of health plans in connection with complex antitrust litigation seeking recovery of overpayments made for brand name drug Flonase due to allege anticompetitive conduct.  Successful settlement achieved.
  • Health Care Services Corp, Inc., et al. v. Mylan Pharmaceuticals, Inc., et al., Case No. 01-2646 (MDL Docket No. 1290, Misc. No. 99-ms-276) (D.D.C.) and Health Care Services Corp, Inc., et al. v. Mylan Pharmaceuticals, Inc., et al., Case Nos. 08-5044, 08-5045 (D.C. Cir.), (consolidated under the MDL captioned as In re Lorazepam & Clorazepate Antitrust Litig., MDL Docket No. 1290, Misc. No. 99-ms-276) (D.D.C.)). Plaintiff's and Lead Appellate Counsel for Plaintiff-Appellee, Health Care Services Corp. and its operating divisions of Blue Cross Blue Shield of Illinois, Blue Cross Blue Shield of Texas, and Blue Cross Blue Shield of New Mexico (HCSC).  Lead counsel for HCSC in antitrust litigation.  After HCSC elected to opt-out of an underlying class litigation/settlement, and after several additional years of litigation, the case was tried to verdict in a month-long jury trial. The jury returned a verdict for HCSC on all claims and for all damages alleged. It was the first indirect purchaser/third-party payor case involving the pharmaceutical industry actually tried to verdict. Following verdict, the damages award for Plaintiffs was trebled and enhanced by the Court and currently amounts to nearly $80 million (over twice the amount of the nationwide class settlement). The case is currently on remand following appellate proceedings with the U.S. court of Appeals for the D.C. Circuit.
  • In re: Plavix Direct Purchaser Antitrust Litigation , Case No. 1:06-cv-00202 (MHW) (S.D. Ohio) and In re: Plavix Indirect Purchaser Antitrust Litigation, Case No. 1:06-cv-00226 (MHW) (S.D. Ohio). Lead Counsel for Plaintiff class members Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals as both direct purchasers and indirect purchasers in conjunction with complex antitrust litigation against Bristol-Myers Squibb Co., Sanofi-Aventis, Sanofi-Synthelabo, Inc., Sanofi-Aventis U.S. L.L.C., Bristol-Myers Squibb Sanofi Pharmaceutical Holding Partnership, and Apotex Corporation seeking recovery of overpayments due to Defendants' alleged anticompetitive conduct in the market for clopidogrel bisulfate tablets (including Plavix®).
  • In re: Vioxx Marketing Fraud Litigation, (619-TPP) (N.J. Sup. Ct. - Atlantic County Division). Lead Plaintiff's counsel for Excellus Health Plan, Inc., Blue Cross Blue Shield of Minnesota, Blue Cross, Blue Shield of Nebraska, and Blue Cross of Idaho in, respectively, individual actions captioned as: Excellus Health Plan, Inc., et al. v. Merck, Inc., Case No. L-4354-08 (N.J. Sup. Ct. - Atlantic County Division), Blue Cross Blue Shield of Minnesota, et al. v. Merck, Inc., Case No. L-4355-08 (N.J. Sup. Ct. - Atlantic County Division), Blue Cross and Blue Shield of Nebraska, et al. v. Merck, Inc., Case No. L-4356-08 (N.J. Sup. Ct. - Atlantic County Division), and Blue Cross of Idaho Health Service, Inc. v. Merck, Inc., Case No. L-3019-09 (N.J. Sup. Ct. - Atlantic County Division). These actions sought recovery of overpayments for the prescription drug Vioxx® based on state statutory and common law claims due to alleged marketing fraud. After intensive litigation, including discovery and dispositive motions, successful settlements were achieved.
  • In re: Vioxx Products Liability Litigation, Case No. MDL 1657 (E.D. La.). Individual Plaintiffs' Counsel for group of health insurers/third party payors seeking subrogation recovery against proceeds to be paid from $4.85 billion settlement to claimants who were members of and received health benefits for the treatment of Vioxx-related conditions. After litigating on our clients' behalf, a settlement was achieved through which a lien resolution program was established to allow for the efficient and effective subrogation recovery by health insurers/third party payors through the underlying settlement.
  • In re: Oxycontin Antitrust Litigation, Case No. 1:04-md-01603 (SHS) (S.D.N.Y.). Lead Counsel for Plaintiff class members Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals as both direct purchasers and indirect purchasers in conjunction with complex antitrust litigation against Purdue Pharma L.P seeking recovery of overpayments made by Kaiser due to alleged anticompetitive conduct in the market for OxyContin® and its generic equivalents. After extensive litigation, settlements have been reached in principle and are pending.
  • U.S. ex rel. Bradford Hunt, et al. v. Merck-Medco Managed Care, LLC, et al., Case No. 00-cv-737 (E.D. Pa.). Plaintiffs'/Relators' Counsel in qui tam action under the False Claims Act alleging fraud by a national pharmacy benefit management company (PBM) related to services performed for federal health plans. The Government intervened in the case, which was litigated aggressively for several years, and which was settled for approximately $185 million just prior to summary judgment/trial. It is one of the largest False Claims Act settlements and was the largest civil settlement in Pennsylvania in 2006-2007. See U.S. ex rel. Hunt, et al. v. Merck- Medco Managed Care, LLC, et al. , 336 F. Supp. 2d 430 (E.D. Pa., 2004); U.S. ex rel. Hunt, et al. v. Merck- Medco Managed Care, LLC, et al., 340 F. Supp. 2d 554 (E.D. Pa. 2004); U.S. ex rel. Hunt, et al. v. Merck- Medco Managed Care, LLC, et al., 223 F.R.D. 330 (E.D. Pa. 2004).
  • In re: Buspirone Antitrust Litigation, MDL No. 1413 (S.D.N.Y.) . Lead Counsel for Plaintiff class members Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals as both direct purchasers and indirect purchasers in conjunction with complex antitrust litigation against Bristol-Myers Squibb (BMS), Danbury Pharmacal, Inc., Watson Pharmaceuticals, Inc., and Watson Pharma, Inc. It was alleged that BMS unlawfully impaired the ability of generic manufacturers from entering the buspirone market to compete with its buspirone product sold under the brand name BuSpar®. The case settled following dispositive motions, with direct purchaser/payors receiving approximately $220 million and indirect purchaser/health plans and payors receiving approximately $90 million. Kaiser received millions of dollars through these settlements and its recovery, net of attorneys' fees, was in excess of 100% of its overpayments. Kaiser also received an award of attorneys' fees and costs through the direct purchaser class settlement.
  • Oncology & Radiation Associates, P.A. v. Bristol Myers Squibb Co., et al., Case No. 1:01-cv-02313 (D.D.C.). Lead Counsel for Plaintiff class members Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals as both direct purchasers and indirect purchasers in conjunction with complex antitrust litigation against Bristol-Myers Squibb (BMS) and American BioScience, Inc. It was alleged that BMS unlawfully monopolized the U.S. market for paclitaxel, a cancer drug discovered and developed by the United States Government, which BMS sold under the brand name Taxol®. BMS' scheme included a conspiracy with American BioScience, Inc., a generic manufacturer, to block generic competition. The case settled following dispositive motions for more than $65 million. Kaiser received millions of dollars through this settlement.
  • Blue Cross Blue Shield of Michigan, et al. v. Aventis S.A., et al., Case No. 2:01-cv-72806 (E.D. Mich.). Plaintiffs' Counsel for Blue Cross and Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan, Blue Cross and Blue Shield of Minnesota, and Excellus Blue Cross Blue Shield in conjunction with complex antitrust litigation against Aventis S.A. and Andrx seeking recovery of overpayments due to Defendants' alleged anticompetitive conduct in the market for Cardizem CD®. After these Plaintiffs elected to opt-out of underlying indirect purchaser class litigation and after intensive opt-out litigation, a successful settlement was achieved.
  • In re: Cardizem CD Litigation, MDL No. 1278 (E.D. Mich.). Counsel for Plaintiff class members Kaiser, United Healthcare, Blue Cross and Blue Cross Blue Shield of Michigan, Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan, Blue Cross and Blue Shield of Minnesota, and Excellus Health Plan, Inc. in conjunction with complex antitrust litigation seeking recovery of overpayments for Cardizem CD® and related products based on alleged anticompetitive conduct of Defendants relative to a "reverse" payment settlement whereby Aventis would pay Andrx (the maker of an FDA-approved, therapeutically equivalent, generic substitute for Cardizem CD®) millions of dollars to delay the entry of the less-expensive Andrx product.  After extensive litigation, the case settled and multi-million recoveries were achieved for those electing to participate in the settlement, while others (as referenced above) elected to opt-out and pursued successful independent recovery litigation.
  • In re: Lorazepam & Clorazepate Litigation, MDL Docket No. 1290, Misc. No. 99-ms-00276 (D.D.C.). Counsel for Plaintiff class members, including 17 health insurers/third party payors in conjunction with complex antitrust litigation against Mylan Laboratories, Mylan Pharmaceuticals, Gyma Corporation, and Cambrex Corporation seeking recovery of overpayments due to Defendants' anticompetitive conduct in the markets for lorazepam (generic equivalent of Ativan®) and clorazepate (generic equivalent of Tranxene®). The indirect purchaser component of the settlement was approximately $35 million. Although the majority of the individual member of our group elected to participate in the settlement, some of our health plan/payor clients, including HCSC (as referenced above) elected to opt-out and pursued successful independent recovery litigation.
  • Blue Cross of California, et al. v. SmithKline Beecham, et al., Case No. 97-cv-01795 (D. Conn.). Plaintiffs' Counsel for a large group of 37 health insurers/third party payors against SmithKline Beecham for alleged unlawful laboratory services based on RICO and common law fraud claims. After intensive litigation, a substantial settlement (confidential) was ultimately achieved.
  • In re: Synthroid Marketing Litig., Case No. 1:97-cv- 06017 (N.D. Ill.). Plaintiffs' Counsel for a large group of 18 health insurers/third party payors in conjunction with complex litigation against Knoll Pharmaceutical Company/BASF seeking recovery of overpayments due to alleged anticompetitive conduct of Knoll by misleading physicians and patients into keeping patients on Synthroid® despite knowing that less costly, but equally effective drugs were available. This case resulted in a settlement of $87.4 million settlement with Knoll and its parent company, BASF Corporation, on behalf of a class of all consumers who purchased Synthroid®. Blue Cross and Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan and Blue Cross and Blue Shield of Minnesota – opted-out and filed their own case, which ultimately settled on favorable terms.

Miscellaneous Notable Matters

  • State of Florida v. Crosley Green in State of Florida v. Crosley Green, Case No. 051989CF004942AXXX (Cir. Ct. 18th Jud. Cir., Brevard Co., FL). Co-Lead Post-Conviction Counsel in pro bono/death penalty case for Florida inmate, Crosley Green, who had been sentenced death and confined on Death Row, awaiting execution, for 19 years. As a result of our initial efforts, we succeeded in having Mr. Green's death sentence set aside/vacated. Currently, we are pursuing federal habeas and other relief in addition to parole for Mr. Green.
  • Monika Nickerson, et al. v. United States, Case No. 1:03-cv-00909 (D. Col.). Lead Plaintiffs' counsel in medical malpractice case against the United States/U.S. Department of the Army brought under the Federal Tort Claims Act. After extensive litigation and prior to trial, a successful settlement was achieved.
  • Matthew Dahl, et al. v. United States, (D.D.C.). Lead Plaintiffs' counsel in medical malpractice case against the United States/U.S. Department of the Army brought under the Federal Tort Claims Act. The case resulted in a successful settlement in favor of Plaintiffs of more than $1.5 million.
  • Chesapeake Center, Inc. v. Blue Cross and Blue Shield of North Carolina, et al., (Circuit Court, Fairfax Co., VA). Lead Defense Counsel for Anthem Blue Cross and Blue Shield in a case involving a payment dispute under the federal TRICARE Program where Anthem served as an intermediary. After extensive litigation, the case against Anthem was dismissed.
  • Medassist-Op, Inc. v. Donna Shalala, et al, Case No. 1:00-cv-01829 (D.D.C.). Lead Defense Counsel for AdminaStar Federal in a case involving a payment dispute under federal health programs where AdminaStar Federal served as an intermediary. After extensive litigation, the case against AdminaStar Federal was dismissed.
  • Keila Duncan, et al. v. United States, Case No. 97-cv-01248 (D. Md.). Co-Lead Defense/Trial Counsel for the U.S. Department of the Navy in medical malpractice (obstetrical/wrongful death) case brought against the Navy under the Federal Tort Claims Act. The case was tried to judgment in favor of the U.S. Government/U.S. Department of the Navy.

Professional Associations

  • American Bar Association: (ABA Advisory Board Member, 2006 - present) Criminal Law, Health Law (Co-Chair Ethics and Professionalism Committee, 2012 – present; Vice-Chair, e-Source and Member, Editorial Board), Litigation, and Administrative Law and Regulatory Practice Sections (past Vice Chair, Criminal Process Committee)
  • American Health Lawyers Association: Fraud & Abuse, Self-Referrals, and False Claims Section
    Bar Association of the District of Columbia
  • Food and Drug Law Institute
  • Vermont Bar Association

Community/Civic/Volunteer Work

The Oasis School (Sultan Hamud, Kenya), Member, International Board of Directors


Affiliations

Admitted to practice:
Supreme Court of the United States
U.S. Court of Appeals for the District of Columbia Circuit
U.S. Court of Appeals for the Eleventh Circuit
U.S. Court of Appeals for the Third Circuit
U.S. Court of Appeals for the Fourth Circuit
U.S. Court of Appeals for the Armed Forces
U.S. District Court for the District of Maryland
U.S. District Court for the District of Columbia
U.S. District Court for the District of Colorado
U.S. Court of Federal Claims
U.S. Tax Court
State of Vermont
District of Columbia

Speeches & Presentations

  • "FCA Qui Tam Relator Cross-Examination," ABA FCA Trial Institute, Denver, CO (June 3-5, 2015). Presenter: Robert T. Rhoad.
  • "Health Care Recovery," Crowell & Moring's In-House Recovery Conference, Dana Point, CA (January 19-20, 2015). Presenter: Robert T. Rhoad.
  • "What Will the New Year Bring: Procurement Fraud," Crowell & Moring Webinar (January 7, 2015). Presenters: Robert T. Rhoad, Brian T. McLaughlin, and Jason C. Lynch.
  • "Recovery Action Scene," Crowell & Moring's Healthcare Ounce Of Prevention Seminar (HOOPS), Washington, D.C. (October 27-28, 2014). Presenters: Daniel A. Sasse and Robert T. Rhoad.
  • "Internal Investigations: Issues, Pitfalls, and Best Practices," Defense Research Institute's Government Enforcement and Corporate Compliance Seminar (July 24-25, 2014). Moderator: Ty E. Howard; Presenters: Robert T. Rhoad, Timothy L. Sturm, and Ricardo J. Zayas.
  • "Trying False Claims Act Cases: A View from the Defense," Grant & Eisenhofer's Qui Tam Practice and American Association of Justice's Qui Tam Litigation Group's 2014 Qui Tam Litigation Speaker Series (July 11, 2014). Presenters: Robert T. Rhoad and Brian T. McLaughlin.
  • "Seeking Clarity on False Claims Act Damages and Penalties," Bates White Webinar (July 1, 2014). Presenters: Robert T. Rhoad, David Osinski, Kirsten Mayer and David J. Fischer.
  • "Strategies For Protecting Internal Investigations From Disclosure," American Bar Association Health Law Section Healthcare Litigation & Risk Management Interest Group Webinar (May 21, 2014). Presenters: Robert T. Rhoad and Jonathan Cone.
  • "Federal Health Care Programs: New FCA Enforcement Risks in a Post-ACA World," OOPS 2014, Crowell & Moring's 30th Annual Ounce of Prevention Seminar, Washington, D.C. (May 13-14, 2014). Moderator: Robert T. Rhoad; Presenters: Jacinta Alves and Troy A. Barsky.
  • "The Rearview Mirror: Lessons Learned From This Year's Trial Victories," Crowell & Moring Seminar/Webinar (April 22, 2014). Presenters: Robert T. Rhoad, Gregory D. Call, Kevin C. Mayer, Linda B. Popejoy, Keith J. Harrison, Brian T. McLaughlin, Mana Elihu Lombardo, Nathaniel P. Bualat, and Jeffrey H. Rutherford.
  • "Life Science Companies: Navigating Ethical Dilemmas," ABA Health Law Section's 15th Annual Conference on Emerging Issues in Healthcare Law (February 27, 2014). Co-Presenter: Robert T. Rhoad.
  • "The Potential Conflict Issues Attorneys Face in Representing Life Science Companies," ABA Health Law Section's 15th Annual Conference on Emerging Issues in Healthcare Law (February 27, 2014). Presenter: Robert T. Rhoad.
  • "False Claims Act and Health Plan Risk," Crowell & Moring's Healthcare Ounce of Prevention Seminar (HOOPS) (January 30, 2014). Presenters: Robert T. Rhoad and Troy A. Barsky.
  • "New Areas of Potential Legal Risk Under the ACA, the False Claims Act, and Related Laws," America's Health Insurance Plans Webinar (December 17, 2013). Presenters: Robert T. Rhoad and Arthur N. Lerner.
  • "Navigating Stormy Seas: Ethical Issues in Qui Tam Litigation under the False Claims Act," American Bar Association Washington Healthcare Summit (December 10, 2013). Presenters: Robert T. Rhoad, Susan Winkler, Marc Raspanti, and Andrew Demetriou.
  • "Fraud and Abuse Bootcamp Webinar Series Part VI: Trends In Government Enforcement," American Health Lawyers Association Webinar (July 17, 2013). Presenters: Robert T. Rhoad, Tony R. Maida, Linda A. Wawzenski, and Kevin E. Raphael.
  • "FCA Witness Examination," ABA FCA Trial Institute, Washington, D.C. (June 5-6, 2013). Presenter: Robert T. Rhoad.
  • "False Claims Act Developments," OOPS 2013, Crowell & Moring's 29th Annual Ounce of Prevention Seminar, Washington, D.C. (May 15-16, 2013). Moderator: Robert T. Rhoad; Presenter: Andy Liu, Mana Elihu Lombardo, and Brian T. McLaughlin.
  • "Ethics: Honoring Your Ethical Obligations While Defending Health Care Providers and Entities During an Investigation," ABA Health Law Section’s 14th Annual Conference on Emerging Issues in Healthcare Law (February 21, 2013). Co-Presenter: Robert T. Rhoad.
  • "What Will the New Year Bring? Headlines, Headaches, and Legal Developments for Government Contractors to Watch in 2013," Crowell & Moring webinar (January 16, 2013). Co-Presenter: Robert T. Rhoad.
  • "False Claims Act and Mandatory Disclosure Requirements for Federal Contractors,” Association of Corporate Counsel webinar (January 15, 2013). Co-Presenter: Robert T. Rhoad.
  • "New False Claims Act Exposures and Government Investigation Tips for Health Plans," Crowell & Moring's Healthcare Ounce of Prevention Seminar (HOOPS- Minnesota) (September 13, 2012). Presenters: Robert T. Rhoad and Christopher K. Lui.
  • "False Claims Act Risks Areas for Health Care Entities," Healthways Seminar (August 3, 2012). Presenter: Robert T. Rhoad.
  • "New False Claims Act Exposures and Government Investigation Tips for Health Plans," Crowell & Moring's Healthcare Ounce of Prevention Seminar (HOOPS) (June 21-22, 2012). Presenters: Robert T. Rhoad and Christopher K. Lui.
  • "False Claims Act: Key Provisions and Current Trends in Compliance and Enforcement," L-2 Federal Resources Webinar (June 14, 2012). Presenters: Robert T. Rhoad and Dalal Hasan.
  • "False Claims Act: Recent Developments and Their Impact on Compliance and Enforcement," Crowell & Moring's 2012 Ounce of Prevention Seminar (OOPS), Washington, D.C. (May 9-10, 2012). Co-Speakers: Robert R. Rhoad, David O’Brien, Brian Tully McLaughlin, and Dalal Hasan.
  • "2011 in Review: Trends in Health Care Fraud Enforcement," American Bar Association 26th Annual National Institute on White Collar Crime (March 2, 2012). Presenter: Robert T. Rhoad.
  • "Settling False Claims Act Cases in the Healthcare Fraud and Enforcement World: Tips and Traps for Providers and Payors," American Health Lawyers Association’s Fraud & Compliance Forum (September 27, 2011). Co-Presenter: Robert T. Rhoad.
  • "False Claims Act Developments: Congress Opens the Floodgates While Courts Mop Up The Mess," 27th Annual Ounce of Prevention Seminar (OOPS), Crowell & Moring, Washington, D.C. (May 24-26, 2011). Co-Presenters: Robert T. Rhoad, Mark R. Troy, Andy Liu, and Jonathan Cone.
  • "Executives and Counsel In the Crosshairs: What Recent Government Efforts to Prosecute Individuals Mean For Your Organization (And You!)," Crowell & Moring webinar (April 7, 2011). Co-Presenters: Robert T. Rhoad, Michael W. Paddock and Chandra K. Westergaard.
  • "Health Care Reform 1 Year Later: Identifying Recent Health Care Reform Trends and the Continuing Effect on the Pharmaceutical Industry," American Conference Institute’s 11th National Forum on Fraud and Abuse in the Sales and Marketing of Drugs Conference (March 29-31, 2011). Presenter: Robert T. Rhoad.
  • "False Claims Briefing," Florida Bar Association Continuing Legal Education Committee and Health Law Section's 2011 Health Law Advanced Topics/Certification Program (March 3-4, 2011). Presenter: Robert T. Rhoad.
  • "Government Investigations and False Claims Act Compliance: New Requirements and New Challenges For Providers," American Health Lawyers Association's 2011 Physicians and Physician Organizations Law Institute / Hospitals and Health Systems Law Institute (February 10-11, 2011). Presenter: Robert T. Rhoad.
  • "Managed Care Strategies After Health Care Reform," Strafford CLE (January 13, 2011). Co-Presenters: Robert T. Rhoad, Christopher Flynn, and James W. Boswell.
  • "What Will the New Year Bring? Top Headlines, Headaches, and Legal Developments for Government Contractors to Watch in 2011," Crowell & Moring webinar (January 12, 2011). Co-Presenter: Robert T. Rhoad.
  • "State & Federal Fraud And Abuse Enforcement Priorities," American Conference Institute's National Forum on Clinical Integration (November 16-17, 2010). Presenter: Robert T. Rhoad.
  • "Health Care False Claims Act Cases: Is it a federal case? Is it a state case? Is it all of the above in many permutations, all at various stages of development?," Practising Law Institute's False Claims Litigation 2010 Conference (November 5, 2010). Presenter: Robert T. Rhoad.
  • "Department of Defense and General Services Administration Procurement Fraud Matters," Practising Law Institute's False Claims Litigation 2010 Conference (November 5, 2010). Presenter: Robert T. Rhoad.
  • "False Claims Briefing," Florida Bar Association Continuing Legal Education Committee and Health Law Section's Second Annual Fundamentals of Florida Health Care Law Conference (September 17, 2010). Presenter: Robert T. Rhoad.
  • "Impact Of The False Claims Act Amendments For Hospital Systems And Anticipating A Rise In Qui Tams," National Legal & Compliance Summit On Health Care Enforcement (June 22, 2010). Presenter: Robert T. Rhoad.
  • "More Exposure And More Risk: Fraud And Abuse Risks In A 'Health Reform' World," Law and Regulatory Affairs Health Care Compliance Seminar (June 12, 2010). Co-Presenters: Robert T. Rhoad and Arthur N. Lerner.
  • "Contract Fraud: One Year After FERA," Caught in the Federal Procurement Fish Bowl, 26th Annual Ounce of Prevention Seminar (OOPS), Crowell & Moring, Washington, D.C. (May 26-27, 2010). Presenters: Mark R. Troy, Robert T. Rhoad, Andy Liu, and Mana E. Lombardo.
  • "Blues Beware: Recent False Claims Act Amendments And Their Impact On Health Care Plans," Blue Cross Blue Sheild Association 44th Annual Lawyers' Conference (May 13, 2010). Presenter: Robert T. Rhoad.
  • "Fox In The Hen House: Dealing With The Whistleblower Employee And Internal Investigation Issues," Crowell & Moring's Healthcare Ounce Of Prevention Seminar (HOOPS) (April 27, 2010). Presenters: Robert T. Rhoad and Kris Meade.
  • "The Blind Side: A Rash of False Claims Act Amendments And New Liability Exposure for Healthcare Entities," Crowell & Moring's 2010 Healthcare Ounce Of Prevention Seminar (HOOPS) (April 26, 2010). Presenters: Robert T. Rhoad and David O'Brien.
  • "Pursuing and Defending Lawsuits Involving Balance Billing, Reimbursement, Physician Tiering and Other Claims," Managed Care Litigation: Emerging Trends in Provider-Plan Disputes, Strafford teleconference/webinar (March 11, 2010). Presenters: Robert T. Rhoad and Chris Flynn.
  • "Affirmative Health Care Cost Recovery Litigation Against Third Parties," Strafford webinar (March 11, 2010). Presenter: Robert T. Rhoad.
  • "Current Trends In Health Care Fraud," Magellan Health Services Legal/Compliance/Security Conference (September 17, 2009). Presenter: Robert T. Rhoad.
  • "Amendments To The False Claims Act," Ethics Resource Center webinar (July 7, 2009). Presenter: Robert T. Rhoad.
  • "Payors Strike Back: Effective Cost Recovery and Affirmative Litigation Strategies," American Health Lawyers' Association 43rd Annual Meeting (June 29, 2009). Presenter: Robert T. Rhoad.
  • "The Future Of Reverse Payment Settlements: Insider's Guide To Imminent Antitrust Policy Changes," American Conference Institute webinar (June 17, 2009). Presenter: Robert T. Rhoad.
  • "Contract Fraud And False Claims," Crowell & Moring's 2009 Ounce Of Prevention Seminar (OOPS) (May 27, 2009). Presenter: Robert T. Rhoad.
  • "Bringing Home the Bacon: Recent Developments And Trends In Third-Party Payor Recovery Actions," Blue Cross Blue Shield Association 43rd Annual Lawyers' Conference (May 7, 2009). Presenter: Robert T. Rhoad.
  • "Emerging Issues in Managed Care Litigation: An Examination of Recovery Actions and Rescission Litigation," Crowell & Moring's 2008 Healthcare Ounce Of Prevention Seminar (HOOPS) (October 21, 2008). Presenter: Robert T. Rhoad.
  • "The Future Of False Claims Act Enforcement In Health Cases: Recent Judicial And Legislative Developments," Crowell & Moring's Healthcare Ounce Of Prevention Seminar (HOOPS) (October 20, 2008). Presenter: Robert T. Rhoad.
  • "Contractors At War: The False Claims Act," Crowell & Moring's 2008 West Coast Ounce Of Prevention Seminar (WOOPS) (April 29, 2008). Presenter: Robert T. Rhoad.
  • "Iraq Reconstruction Contracting: Navigating The Legal Minefield," National Contract Management Association, Saguaro Chapter Conference (April 24, 2008). Presenter: Robert T. Rhoad.
  • "Battlefield Contracting And The False Claims," Crowell & Moring's 2008 Ounce Of Prevention Seminar (OOPS) (April 22, 2008). Presenter: Robert T. Rhoad.
  • "Overseas Health Insurance Markets - Potential Pitfalls of Expansion: Global Privacy Issues, International Compliance, and Foreign Corrupt Practices Act," Crowell & Moring's 2007 Healthcare Ounce Of Prevention Seminar (HOOPS) (October 2007). Moderator: Robert T. Rhoad.
  • "Successful False Claims Act Defense Strategies: The Custer Battles Case," National Contract Management Association Aerospace and Defense Conference (July 27, 2007). Presenter: Robert T. Rhoad.
  • "Employee Handbooks & Whistle Blower Provisions: Are You in Compliance?," National Constitution Conference (January 4, 2007). Presenter: Robert T. Rhoad.
  • "Substantive and Procedural Motions," District of Columbia Bar Association CLE Program Pre-Trial Skills Series (October 26, 2006). Co-Presenter: Robert T. Rhoad.
  • "Go To Jail. Go Directly To Jail: Criminal Prosecutions Predicated on the Government's Disagreement with Your Interpretation of Complex Regulations," ABA Administrative Law Conference (November 1, 2001). Presenter: Robert T. Rhoad.


Publications



Client Alerts & Newsletters



In the News

  • 4 Issues To Watch In Amarin’s Off-Label Marketing Suit
    May 12, 2015 — Law360

    Robert T. Rhoad, a Washington, D.C.-based Healthcare partner, discusses with Law360 the implications of Amarin Pharma Inc.'s constitutional challenge to the Food and Drug Administration's restrictions on off-label marketing. "The issue couldn't be teed up more clearly for the court," Rhoad said. Rhoad remarks further that the prospect of future policy tweaks is not a sufficient reason to deny relief to Amarin. "If I was a judge, I would give that zero to very little weight," he said.


  • 5 Issues Gov't Contractors Need To Know About In 2015
    January 7, 2015 — Law360

    Law360 highlights the firm's Government Contracts Group and the recent webinar the Group conducted titled, "What Will the New Year Bring for Government Contractors?" This article details the five issues federal contractors should pay attention to in 2015, as forecasted by Crowell & Moring attorneys in their preview of the year ahead.


  • FCA Free Speech Defense Tested In DOJ-PhRMA Fight
    September 19, 2014 — Law360

    Washington, D.C.-based partner and co-chair of the firm's False Claims Act Practice, Robert T. Rhoad, discusses the Solis v. Millennium case currently taking place in a California federal court between the U.S. Department of Justice and Pharmaceutical Research and Manufacturers of America (PhRMA) with opposing sides clashing over whether the First Amendment always shields honest off-label promotion. "What the industry really wants here are bright lines and safe harbors," Rhoad said. "And to the extent they get a decision here saying truthful speech cannot be used to support a False Claims Act case, I think that would be a huge victory."


  • 3 Tips For Workable FCA Release Programs
    July 25, 2014 — Law360

    Robert T. Rhoad, co-chair of the firm's False Claims Act Practice, shared some tips with Law360, stemming from the rise of qui tam False Claims Acts lawsuits. "You're never going to fully eliminate your exposure," Rhoad told Law360. "But what you can try to do is mitigate it as much as you possibly can. Be forward-looking at the time you employ someone, where you have an employment agreement that obligates them to disclose any information that they may become aware of that might suggest any violation of federal or state law."


  • Health Care Cases To Watch In The 2nd Half Of 2014
    July 23, 2014 — Law360

    Washington, D.C.-based Government Contracts Group partner and co-leader of the firm's Government Procurement Fraud/False Claims Act team, Robert T. Rhoad, discussed the impact of closely-watched, FCA case, Kellogg Brown & Root Services Inc. et al. v. U.S. ex rel. Carter. The U.S. Supreme Court recently agreed to hear this case, which has the potential to significantly weaken the six-year statute of limitations law for the Wartime Suspension of Limitations Act in FCA cases. 


  • 5 Tips For Crafting Multistate FCA Settlements
    July 14, 2014 — Law360

    Robert T. Rhoad, co-chair of the firm's False Claims Act Practice, discussed with Law360 the challenges for health care companies facing increased lawsuits in multiple jurisdictions and decisions over choices in settlement talks. Rhoad addressed specific strategies health care companies can use when crafting FCA settlements.


  • FCA Wave Sparks Debate Over DOJ Power To Boot Weak Suits
    May 2, 2014 — Law360

    Washington, D.C.-based Government Contracts partner and co-leader of the firm's Government Procurement Fraud/False Claims Act team, Robert T. Rhoad, discussed with Law360 the controversy surrounding the DOJ's power as it relates to the department's ability to throw out meritless False Claims Act cases. The article looks at FCA provision - 31 U.S.C. 3730(c)(2)(A) - that allows the government to dismiss complaints over the objections of the person who brought the case.


  • 5 Years After FERA, FCA Landscape Still Unsettled
    April 28, 2014 — Law360

    Washington, D.C.-based Government Contracts partner and co-leader of the firm's Government Procurement Fraud/False Claims Act team, Robert T. Rhoad, discussed with Law360 the fifth anniversary of the passage of the Fraud Enforcement and Recovery Act (FERA), and the impact of new statutory language.


  • Washington Litigation Departments of the Year: Crowell & Moring General Civil Litigation
    June 24, 2013 — National Law Journal

    In the National Law Journal (NLJ) special report "Washington Litigation Departments of the Year," Crowell & Moring was named "Department of the Year" in the "General Civil Litigation" category. For this report, the NLJ editorial team evaluated litigation departments in the nation's capital based on several criteria including biggest wins, revenues, headcounts, and operations. As a result of their research and findings, the team selected six "excellent firms" in this first-ever, Washington, D.C.-based contest. When asked about the firm's key to success, firm chairman and Washington, D.C.-based partner, Kent Gardiner, remarked, "Clients bet on us because we bet on ourselves to win for them, and we collaborate to structure our fees around our ability to achieve success as they define it."

  • 4th Circ. Shows Expired FCA Claims Can Haunt Contractors
    March 27, 2013 — Law360

    Washington, D.C.-based Government Contracts partner, Robert T. Rhoad, discusses implications contractors may face due to a recent Fourth Circuit court ruling on FCA claims.


  • FCA Expansion Fight May Land In High Court
    January 28, 2013 — Law360

    Co-leader of the firm's False Claims Act practice and Washington, D.C.-based partner, Robert T. Rhoad, offers his insight on the Sixth Circuit's recent ruling in USA v. Allison Engine Co. According to the article, the ruling deepens a circuit split over whether 2009 amendments to the False Claims Act that dramatically expanded the range of conduct targeted by the law can apply retroactively. "In response to the Supreme Court's decision, Congress passed FERA (Fraud Enforcement and Recovery Act), which effectively overruled the court's holding and did precisely that against which the court cautioned - it transformed the FCA into an 'all-purpose anti-fraud statute," said Rhoad.


  • False Claims Act – Special Report "Federal Procurement Trends for 2011": Practitioners Say Expansion of FCA Liability, Congressional Oversight Means 'Open Hunting Season' on Contractors
    January 24, 2011 — BNA Federal Contracts Report

    Government Contracts Group partner Robert T. Rhoad and White Collar & Regulatory Enforcement Group partner Kelly T. Currie are featured in BNA's "Federal Procurement Trends for 2011" special report in a piece about the controversy surrounding the governments effort to curtail waste, fraud, and abuse. For example, according to the article, "the False Claims Act is a primary tool for punishing those said to be guilty of overbilling or otherwise defrauding the federal government. But contracting practitioners (say) that recent efforts to increase the government's ability to recover under the FCA place unnecessary and detrimental risks on contractors. They predict that these risks will increase in the coming year as the government steps up its efforts to rein in fraud and collect much-needed funds for cash-strapped agencies. 

    According to Rhoad, "The government has used the FCA successfully since 1986 to recover money from contractors accused of fraud…With the Fraud Enforcement and Recovery Act of 2009 (FERA) amendments to the FCA, that trend will escalate."

    According to Currie, "Congress is sending all kinds of signals that it’s going to apply close scrutiny because government spending is a big focus…I think there’s an overall tone in Washington that's calling for more oversight, so companies have to be prepared to defend themselves on multiple fronts."

  • New DOJ Powers on Horizon
    November 20, 2009 — The Daily Journal

    Robert T. Rhoad, member of Crowell & Moring’s False Claims Act and qui tam litigation team and partner in the firm’s Government Contracts, Health Care, and Antitrust groups, was featured for his comments on the Justice Department’s new powers to obtain information from government fraud suspects and share it with other agencies and private litigants. According to Associate Attorney General Tony West, “the expanded authority would be an ‘important tool’ and a ‘force multiplier’ in the effort to crack down on government fraud.

  • Changes to FCA Increase Contractor Liability
    June 19, 2009 — Employment Law360

    Crowell & Moring LLP Government Contracts Group partner Robert T. Rhoad is featured for his comments on President Obama signing into law the Fraud Enforcement and Recovery Act, which made the most sweeping revisions to the False Claims Act since 1986.

  • Supreme Court's Allison Engine Decision's Potential Impact On False Claims Act Enforcement In Healthcare Cases
    August 15, 2008 — ABA Health eSource

    Crowell & Moring Healthcare Group partner Robert T. Rhoad writes about the Supreme Court's decision in Allison Engine Co. V. United States ex rel. Sanders, et al.. The Court's decision in the so-called "Allison Engine" case outlines what must be proven to make a liability claim under the false claims act.

  • Theories Abound in WellCare Raid
    October 29, 2007 — Modern Healthcare

    Crowell & Moring Healthcare Group partner Robert Rhoad is featured in Modern Healthcare for his comments on the governments probe into WellCare Health Plans. 


Firm News & Announcements

Jun.02.2015 CBS "48 Hours" Features Crowell & Moring Pro Bono Client Crosley Green
Jan.22.2015 Crowell & Moring's Antitrust Group Featured in Global Competition Review's 15th Edition "GCR 100"
Jan.09.2015 Crowell & Moring's Government Contracts Group Named to Law360's "Practice Groups of the Year" for Fifth Consecutive Year
Sep.30.2014 Super Lawyers 2014 Recognizes 90 Crowell & Moring Attorneys
Jun.24.2013 Crowell & Moring Recognized by National Law Journal as Washington, D.C. "General Civil Litigation" Department of the Year
Jan.29.2013 Crowell & Moring Releases Report, "Litigation Forecast 2013"
Jul.09.2010 Former Florida Death Row Inmate Crosley Green Petitions For New Trial
Mar.17.2009 Crowell & Moring Client USA Environmental Vindicated In False Claims Act Lawsuit
Oct.08.2007 Crowell & Moring's Expanding Health Care Litigation Practice Gains Experienced Litigator
Background image